by | Nov 4, 2024 | Uncategorized
Inherited variants in DNA repair genes such as BRCA1 and BRCA2 may increase risk for multiple myeloma, according to results of a retrospective study.Patients with pathogenic germline variants exhibited increased likelihood of having a family or personal history of...
by | Oct 28, 2024 | Uncategorized
Decreasing the amount of dexamethasone that individuals with newly diagnosed multiple myeloma received did not affect survival, according to a secondary analysis of completed clinical trials.Nearly 70% of patients treated with dexamethasone required dose reductions...
by | Oct 24, 2024 | Uncategorized
The addition of daratumumab to maintenance lenalidomide extended PFS for patients who underwent stem cell transplant for newly diagnosed multiple myeloma, according to study results.The combination reduced risk for disease progression or death by 47% compared with...
by | Oct 23, 2024 | Uncategorized
A new initiative to rapidly place individuals with acute myeloid leukemia or myelodysplastic syndrome in clinical trials based on their genomic profiles has opened in the United States and Canada.The myeloMATCH program will enroll patients into different studies as...
by | Oct 14, 2024 | Uncategorized
A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.Nearly all patients with multiple myeloma eventually relapse. CAR...
by | Oct 9, 2024 | Uncategorized
Source: CureToday articles Ninlaro, Thalomid and dexamethasone followed by Ninlarlo maintenance may improve durability of response in myeloma after stem cell transplantation relapse. Read More
